BRCA2 reversion mutation confers resistance to olaparib in breast cancer
Key Clinical Message A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer. Abstract A 34‐year‐old woman with breast cancer and BRCA2: p.Gln3047Ter was treated with olaparib. After t...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2023-06-01
|
| Serie: | Clinical Case Reports |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/ccr3.7537 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|